Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1628 1629
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17541461 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Final Rejection | ANTECIP BIOVENTURES II LLC |
| 18269390 | CLATHRATE IN WHICH EQUOL IS INCLUDED IN CYCLODEXTRIN, EQUOL-ABSORBENT COMPOSITION CONTAINING SAID CLATHRATE, AND PRODUCTION METHOD THEREFOR | Final Rejection | DAICEL CORPORATION |
| 18570552 | ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID | Non-Final OA | LG CHEM, LTD. |
| 18553480 | FORMULATION | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18853699 | PROCESS FOR MAKING A KRAS G12C INHIBITOR | Non-Final OA | ELI LILLY AND COMPANY |
| 17928765 | USE OF 2-HOBA TO TREAT ATHEROSCLEROSIS | Final Rejection | Vanderbilt University |
| 18287690 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18666636 | METHODS OF TREATING DISORDERS ASSOCIATED WITH EYA OVEREXPRESSION AND MUTATIONS | Non-Final OA | The Board of Regents of the University of Texas System |
| 18018924 | COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS | Final Rejection | Arizona Board of Regents on Behalf of the University of Arizona |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy